Health Canada cleared both products in April, covering osteoporosis and bone indications
Two more denosumab biosimilars are now on the Canadian market, approved for every indication of the reference products Prolia and Xgeva.
According to Fresenius Kabi Canada, the company has launched Conexxence at 60mg/mL and Bomyntra at 120mg/1.7mL, both of which received Health Canada approval in April.
Fresenius Kabi lists approved indications for Conexxence as the treatment of osteoporosis in postmenopausal women and men at increased risk of fracture, treatment-induced bone loss, and increasing bone mass in patients at high risk of fracture.
Bomyntra, the company states, is approved for the prevention of skeletal-related complications in patients with bone metastases from solid tumours, the prevention of skeletal-related events in patients with multiple myeloma, and the treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity.
In its announcement, Fresenius Kabi said the launch of its denosumab biosimilars widens access to biologic therapies and helps health systems manage costs.
Niamh Furey, senior vice president of biopharma Europe and rest of world (ROW), said the company is “the first and only biosimilar company to offer a ready-to-use pre-filled syringe presentation for oncology indications of denosumab in Canada.”
The active ingredient in both products is denosumab, a monoclonal antibody that inhibits RANKL.
In Conexxence, the company states this reduces bone resorption and increases bone mass.
In Bomyntra, it reduces bone destruction associated with malignancy. Both are administered by subcutaneous injection.
Development work for each product included analytical, non-clinical, and clinical studies confirming equivalent efficacy and comparable safety to Prolia, Fresenius Kabi said, including a Phase 1 pharmacokinetic and pharmacodynamic trial in healthy volunteers and a Phase 3 trial, LUMIADE-3.
Conexxence is approved in Canada, the US, and the EU for the treatment of osteoporosis in postmenopausal women and men at increased risk of fracture, and for bone loss associated with hormone ablation in cancer patients.
Bomyntra holds approvals in the same three markets for the prevention of skeletal-related events in adults with advanced malignancies involving bone and for the treatment of giant cell tumour of bone.
Fresenius Kabi’s biosimilars marketed in Canada also include Idacio (adalimumab), Tyenne (tocilizumab), and Otulfi (ustekinumab), with additional biosimilars in development.


